A review of Campath in autoimmune disease: Biologic therapy in the gray zone between immunosuppression and immunoablation

Bone marrow transplant

1999 • 2,452 citations

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1997 • 1,651 citations

A COMPUTER-ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS

1977 • 1,027 citations

"Infectious" Transplantation Tolerance

1993 • 890 citations

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1999 • 467 citations

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1999 • 456 citations

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1999 • 426 citations

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

2001 • 411 citations

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

1997 • 365 citations

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1989 • 356 citations

The CAMPATH‐1 antigen (CDw52)

1990 • 334 citations

Humanised monoclonal antibody therapy for rheumatoid arthritis

1992 • 316 citations

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

2001 • 286 citations

Recombinant Human Relaxin in the Treatment of Scleroderma

2000 • 267 citations

Childhood dermatomyositis: Factors predicting functional outcome and development of dystrophic calcification

1983 • 248 citations

Course of Crohn's disease after allogeneic marrow transplantation

1998 • 228 citations

Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety

2001 • 220 citations

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses

2003 • 211 citations

Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection

1998 • 207 citations

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy

1993 • 205 citations

T CELL DEPLETION WITH CAMPATH-1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION

1988 • 189 citations

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

2004 • 182 citations

Risks of Developing Epstein-Barr Virus–Related Lymphoproliferative Disorders After T-Cell–Depleted Marrow Transplants

1998 • 176 citations

The effect of treatment with Campath‐1H in patients with autoimmune cytopenias

2001 • 174 citations

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients

2003 • 169 citations

Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children.

1998 • 168 citations

CLASSIFICATION AND TREATMENT OF THE JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES

1997 • 163 citations

IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIES

1988 • 152 citations

Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.

1996 • 151 citations

Cyclosporine in systemic sclerosis. results of a forty‐eight–week open safety study in ten patients

1993 • 134 citations

Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia.

1992 • 128 citations

Campath-1H therapy in refractory ocular inflammatory disease

2000 • 127 citations

Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.

1994 • 126 citations

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies

1996 • 122 citations

Long‐term outcome of autoimmune disease following allogeneic bone marrow transplantation

1998 • 119 citations

Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi‐national survey

2000 • 117 citations

Juvenile Dermatomyositis: Pathophysiology and Disease Expression

1995 • 115 citations

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1993 • 111 citations

CAMPATH-1H IN RHEUMATOID ARTHRITIS—AN INTRAVENOUS DOSE-RANGING STUDY

1996 • 107 citations

Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H

2003 • 103 citations

Campath‐1h, a humanized monoclonal antibody, in refractory rheumatoid arthritis

1995 • 103 citations

Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation

1998 • 98 citations

Emergence of oligoclonal t cell populations following therapeutic t cell depletion in rheumatoid arthritis

1995 • 97 citations

Repopulation of blood lymphocyte sub‐populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH‐1H

1996 • 86 citations

Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia

2001 • 80 citations

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

1996 • 80 citations

CAMPATH-1 Monoclonal Antibodies in Bone Marrow Transplantation

1994 • 79 citations

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.

1994 • 77 citations

A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.

1996 • 74 citations

A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].

1991 • 73 citations

Scleroderma--demographics and survival.

1997 • 72 citations

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody campath‐1h administered by daily subcutaneous injection

1995 • 67 citations

Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti‐CD52 monoclonal antibody alemtuzumab (Campath‐1H)

2003 • 65 citations

Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A

1997 • 64 citations

CAMPATH-1M—PROPHYLACTIC USE AFTER KIDNEY TRANSPLANTATION

1989 • 63 citations

Management of Severe Scleroderma with Long-Term Extracorporeal Photopheresis

1998 • 57 citations

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

1997 • 57 citations

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation

2001 • 52 citations

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H

1995 • 50 citations

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.

1990 • 49 citations

Sustained remission of severe resistant autoimmune neutropenia with Campath‐1H

1997 • 42 citations

Assessment of disease activity and its sequelae in children and adults with myositis

1996 • 41 citations

Pilot study of antithymocyte globulin in systemic sclerosis

1996 • 39 citations

WILL MIXED CHIMERISM CURE AUTOIMMUNE DISEASES AFTER A NONMYELOABLATIVE STEM CELL TRANSPLANT?

2001 • 36 citations

Recognition of CD52 allelic gene products by CAMPATH‐1H antibodies

1996 • 35 citations

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.

1996 • 35 citations

Recognition and Management of Scleroderma in Children

2001 • 20 citations

Treatment of refractory autoimmune diseases with ablative immunotherapy

2003 • 20 citations

Semi-Specific Immuno-Absorption and Monoclonal Antibody Therapy in ANCA Positive Vasculitis: Experience in Four Cases

1998 • 20 citations

Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support

2003 • 18 citations

Treatment of transplant rejection: are the traditional immunosuppressants good enough?

2001 • 17 citations

Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance

2001 • 6 citations

Monoclonal Antibody Therapy for Vasculitis

1993 • 2 citations

[Non-specific immunosuppression and multiple sclerosis].

1998 • 2 citations